How much revenue does Haisco Pharmaceutical Group make?

Haisco Pharmaceutical Group reported 3.72 billion CNY in revenue for fiscal year 2024, up 10.9% from 3.36 billion CNY in fiscal year 2023. In Q2 2025 revenue was 1.11 billion CNY.

What is Haisco Pharmaceutical Group's largest business segment?

Parent Company, with 4.40 billion CNY or 50% of segment revenue in fiscal year 2025. Next: Tibet Pharmaceuticals Merger (29%) and Liaoning Hisun (6%).

What companies are similar to Haisco Pharmaceutical Group?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ), Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ), Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS), Humanwell Healthcare (Group) Co.,Ltd. (600079.SS).

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) Stock

About Haisco Pharmaceutical Group Co., Ltd.

Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research co...

At a glance

Haisco Pharmaceutical Group reported revenue of 3.72 billion CNY for fiscal year 2024, up 10.9% from fiscal year 2023, and net income of 395.46 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 1.11 billion CNY, up 18.7% from a year before. Its largest business segment, Parent Company, brought in 50% of segment revenue in fiscal year 2025.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.